Source: Annual Congress 2003 - Asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. L. Shaporova, V. I. Trofimov, T. P. Ses, V. G. Volcovoinova (St Petersburg, Russia). The immunological features of the severe steroid-resistant asthma. Eur Respir J 2003; 22: Suppl. 45, 3019

Member's Comments

No comment yet.

Related content which might interest you: Clinical features of steroid-resistant patients with severe steroid-dependent bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 133s Year: 2004 The glucocorticoid nuclear action peculiarities in the steroid-resistant patients with severe bronchial asthma Source: Eur Respir J 2003; 22: Suppl. 45, 32s Year: 2003 The genetic markers of steroid-resistance in the patients with steroid-dependent bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004 Pathophysiology of severe asthma phenotypes Source: International Congress 2014 – PG05 Severe asthma – highlights from the ERS/ATS workshop Year: 2014 Ykl-40 and phenotyping of severe asthma Source: International Congress 2019 – Immunopathological mechanisms of lung disease Year: 2019 Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021 Management of difficult-to-treat severe asthma Source: Eur Respir Mon 2011; 51: 282-296 Year: 2011 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Identifying asthma features in severe COPD Source: International Congress 2018 – Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS) Year: 2018 Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 Pathophysiology of non-eosinophilic severe asthma Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma Year: 2017 Early-onset allergic severe asthma Source: International Congress 2015 – Severe asthma phenotyping Year: 2015 Omalizumab in children with severe persistent allergic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Pathophysiology of severe non-allergic asthma Source: International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma Year: 2019 Immunotherapy in severe asthma Source: ERS webinar 2021: Immunotherapy in severe asthma Year: 2021 The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 IL-33 in patients with severe uncontrolled allergic asthma Source: International Congress 2017 – "Alarming" immunological patterns in asthma Year: 2017 Benralizumab for severe asthma associated with extra-airway eosinophilic diseases Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Cellular mechanisms underlying steroid-resistant asthma Source: Eur Respir Rev, 28 (153) 190096; 10.1183/16000617.0096-2019 Year: 2019